Replies to post #223178 on Biotech Values

[biotech_researcher]

“Revance launches alone” That would be a disaster..

[DewDiligence]

RVNC—…be prepared for the post launch short attack...probably good for single Digit stock price…

That tactic doesn’t apply to the RT002 launch in glabellar lines. Sales for a cash-pay product in an aesthetic indication generally ramp up quickly, as there are no contracts to be negotiated with third-party payers and PBMs.

p.s. Welcome to iHub. I noticed that this was your first-ever post.